title: Progestogen-only injectable contraceptive: experience of women in Osogbo, southwestern Nigeria.
abstract: BACKGROUND
  Progestogen-only injectable contraceptive is a long-acting contraceptive given intramuscularly to give protection against unwanted pregnancy for a period of 2 or 3 months, depending on the type. Alterations in menstrual pattern are a well known side effect of this effective contraceptive method.
  
  
  OBJECTIVE
  To determine the characteristics of women accepting the method, complications and indications for discontinuation.
  
  
  METHODS
  This was a retrospective review of clients using progestogen-only injectable contraceptive between 1 st January, 2001 and 31 st December, 2009. Relevant information extracted from the case notes was analyzed. Survival analysis was carried out using Log-Rank Chi-square test to measure association over 12-month period of usage. Level of significance was set at P value less than 0.05.
  
  
  RESULTS
  A total of 1,967 women used contraception during the study period and 433 (22.1%) made progestogen-only injectable their method of choice. 199(45.96%) used NET-EN, while DMPA was used by234 (54.04%) women. Many of the women (197, 45.5%) used the method for terminal fertility control. Menstrual abnormality was the commonest (264, 71.4%) complaint about progestogen-only injectable contraceptive, of which amenorrhea was experienced by constituted 176(66.7%). Eighty-three (22.4%) women had discontinued the contraceptive, and menstrual abnormality was the commonest reason for the discontinuation (68, 81.9%). No pregnancy was reported among the women that came for follow up while on the method.
  
  
  CONCLUSIONS
  Short duration of POIC use that is within 12 months is still high. However the main reason for discontinuation was found to be due to menstrual irregularities, hence the need for effective education of the women about this side effect, thus increasing the acceptance and continuation rate of the contraceptive method.
authors.affiliation: Department of Obstetrics and Gynaecology, Ladoke Akintola University of Technology Teaching Hospital, Osogbo, Osun State, Nigeria. ourgodreigns2004@yahoo.co.uk
authors.forename: A S
authors.initials: AS
authors.lastname: Adeyemi
authors.forename: D A
authors.initials: DA
authors.lastname: Adekanle
mesh_terms: D000328:Adult; D000568:Amenorrhea / Q000209:etiology; D016009:Chi-Square Distribution; D003268:Contraception Behavior; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects*; D008599:Menstruation Disturbances / Q000209:etiology*; D009549:Nigeria; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010342:Patient Acceptance of Health Care; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D003271:Contraceptive Agents, Female; D045167:Progesterone Congeners; D017258:Medroxyprogesterone Acetate; C024319:norethindrone enanthate; D009640:Norethindrone